Clinical experience with sulprostone
Brabec, W.; Dapunt, O.; Bichler, A.
Wiener Klinische Wochenschrift 93(6): 193-197
1981
ISSN/ISBN: 0043-5325 PMID: 7281695 Document Number: 174039
Sulprostone (SHB 286, Schering) was used in patients with missed abortion as well as in cases of intrauterine death and hydatid mole (total number=226). In the 1st trimester, a single injection of 25 or 50 mcg was administered into the cervix in order to accomplish preoperative dilatation of the cervix (intramural injection). In the 2nd and 3rd trimesters, Sulprostone was administered either by intravenous (mean dosage, 925 mcg), intragluteal (mean dosage, 540 mcg), or the extraamniotic (mean dosage 660 mcg) routes. After intramural administration, an abortion score of at least 20 according to Csapo was obtained in 78% of the patients. With an intravenous route, the abortion rate was 86%, with an extraamniotic route 74%, and with the intragluteal route 70%. The main use of intramural applications is seen the first 12 weeks of pregnancy in order to ensure nontraumatic dilatation of the cervix. In the 2nd and 3rd trimesters, intravenous and intragluteal administration seem to be superior to the extraamniotic route due to the increased tolerance. (author's)